



聯康生物科技集團有限公司

Uni-Bio Science Group Limited

To: Business Editor [For immediate release]

**PROPOSED ACQUISITION OF ZETHANEL PROPERTIES LIMITED**

\*\*\*\*\*

**FURTHER CONSOLIDATE THE MARKET LEADER POSITION IN THE BIO-PHARMACEUTICAL INDUSTRY**

(24 July 2007, Hong Kong) Uni-Bio Science Group Limited (“Uni-Bio” or the “Group”, SEHK: 690) announced that Lelion, a subsidiary wholly-owned by the Group, has entered into a conditional acquisition agreement with certain independent third parties (“Vendors”) for the purchase of the entire issued share capital of Zethanel Properties Limited (“Zethanel”) for a total consideration of HK\$366,685,000 (the “Acquisition”). An application has been made to the Stock Exchange for the resumption of trading in the securities of the Group with effect from 2:30 p.m. on 25 July 2007.

**Consideration for the Acquisition**

The consideration for the Acquisition could be completed in one of the following options, at the sole election of the Group:

**Option 1**

By the issue of 66,670,000 new Uni-Bio shares as Consideration shares, credited as fully paid, at an issue price of HK\$5.50 each by the Group to the Vendors

**Option 2**

By paying the Vendors collectively a minimum of 36,670,000 and a maximum of 66,670,000 new Uni-Bio Shares as Consideration Shares, credited as fully paid, at an issue price of HK\$5.50 each by the Group to the Vendors, along with an aggregate amount of up to HK\$165,000,000 in cash.

Zethanel is incorporated in the British Virgin Islands. Its only asset is the holding of 深圳市華生元基因工程發展有限公司 (transliteration into English as Shenzhen Watsin Genetech Co., Ltd.) (“Shenzhen Watsin”), which is a wholly-foreign owned enterprise established in the People’s Republic of China (“PRC”). Shenzhen Watsin is principally engaged in the development, manufacturing and marketing of bio-pharmaceutical products. Its main products are bio-therapeutic recombinant human epidermal growth factor (“EGF”) products in liquid preparations primarily indicated for external use for burn and wound care. Watsin’s liquid spray formulation of EGF has been granted a Class I prescription new drug classification by the Ministry of Health in the PRC. Its production plant in Guangdong has obtained GMP certification for the production of bio-science related products. Since early 2007 Uni-Bio’s subsidiary has been the exclusive distributor for Watsin’s EGF products in the PRC (not including Hong Kong, Macau and Taiwan).

For the years ended 31 December 2005 and 31 December 2006, the unaudited net profit after tax of Zethanel and Watsin amounted to approximately RMB 17.9 million and RMB 21.5 million, respectively.

Mr. Tong Kit Shing, Chairman of the Group said, “We are very pleased to announce the acquisition of Shenzhen Watsin. Upon completion of the acquisition, the Group will start to manufacture and distribute its own Class I prescription drug in the PRC. Coupled with the Group’s current strong R&D capability and GMP manufacturing facilities, we believe the acquisition would further strengthen the Group’s position as a leading vertically integrated bio-pharmaceutical company, and would in the long term enhance the Group’s financial performance and enhance shareholders’ return.”

**- End -**

**About Uni-Bio Science Group Limited (SEHK: 0690)**

Uni-Bio Science Group Limited is dedicated to the discovery, development and commercialization of bio-pharmaceuticals through recombinant DNA and other technologies. The Group has commenced research and development into a diversified portfolio of pharmaceutical products at various stages of development, including treatments for type 2 diabetes, osteoporosis, cancer, infectious diseases, inflammatory conditions and immune system disorders.

Released by the Elite Communications Group Limited for and on behalf of Uni-Bio Science Group Limited. For further information, please contact:

Investor Relations

Ms. Cindy Xin

Tel.: 3183 0226

Fax: 2155 9165

Media Relations

Ms. Alice Li

Tel.: 3183 0232

Fax: 2583 9138